10-Q quarterly report · filed Nov 12, 2026

Cardiff Oncology, Inc. (CRDF) Q3 2026 10-Q Quarterly Report

Short answer

Cardiff Oncology, Inc. (CRDF) filed its Q3 2026 10-Q quarterly report on Nov 12, 2026 for the quarter ended Sep 30, 2026. Quarterly revenue was $171,000 (up 42.5% year over year) with net income of −$9M.

Q3 2026 key financials · XBRL

Revenue
$171,000
+42.5% YoY · +64.4% QoQ
Net income
−$9M
+21.3% YoY · +4.1% QoQ
Operating margin
-5391.2%
EPS (diluted)
−$0.11
+35.3% YoY · +21.4% QoQ

Source: XBRL data from the Cardiff Oncology, Inc. (CRDF) Q3 2026 10-Q on SEC EDGAR. USD.

Cardiff Oncology, Inc. Q3 2026 10-Q analysis

AI summary of MD&A and risk factor updates

Management Discussion & Analysis

  • Quarterly revenue $0.2M vs $0.1M YoY
  • R&D expense $5.0M vs $8.2M YoY, SG&A $4.4M vs $3.9M
  • Best program: 30 mg onvansertib plus FOLFIRI/bev, ORR 72.2% vs 42.1% SoC
  • Cash, equivalents and short-term investments $33.8M at September 30, 2026, operating cash use $33.9M
  • Funding projected through Q3 2027, substantial going-concern doubt and additional capital required

Risk Factors

  • No material changes from Form 10-K risk factors for year ended December 31, 2025
  • Carried-forward risks not specified in provided section

Generated from the filing text; verify against the original. 10-K vs 10-Q vs 8-K

Other Cardiff Oncology, Inc. quarterly reports

Ask about this quarter

Compare quarters, check guidance or see what insiders and funds did around the report.